HRP20220972T1 - Oftalmološki pripravci koji sadrže muskarinski antagonist i deuteriranu vodu - Google Patents
Oftalmološki pripravci koji sadrže muskarinski antagonist i deuteriranu vodu Download PDFInfo
- Publication number
- HRP20220972T1 HRP20220972T1 HRP20220972TT HRP20220972T HRP20220972T1 HR P20220972 T1 HRP20220972 T1 HR P20220972T1 HR P20220972T T HRP20220972T T HR P20220972TT HR P20220972 T HRP20220972 T HR P20220972T HR P20220972 T1 HRP20220972 T1 HR P20220972T1
- Authority
- HR
- Croatia
- Prior art keywords
- ophthalmic preparation
- less
- months
- mass
- ophthalmic
- Prior art date
Links
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 title claims 5
- 239000003149 muscarinic antagonist Substances 0.000 title claims 5
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title 1
- 239000006172 buffering agent Substances 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- HEMHJVSKTPXQMS-DYCDLGHISA-M Sodium hydroxide-d Chemical compound [Na+].[2H][O-] HEMHJVSKTPXQMS-DYCDLGHISA-M 0.000 claims 2
- QTBSBXVTEAMEQO-GUEYOVJQSA-N acetic acid-d4 Chemical compound [2H]OC(=O)C([2H])([2H])[2H] QTBSBXVTEAMEQO-GUEYOVJQSA-N 0.000 claims 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims 2
- 230000004379 myopia Effects 0.000 claims 2
- 208000001491 myopia Diseases 0.000 claims 2
- 230000004423 myopia development Effects 0.000 claims 2
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 229930003347 Atropine Natural products 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 229920002413 Polyhexanide Polymers 0.000 claims 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229960000396 atropine Drugs 0.000 claims 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical group O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims 1
- 229960002028 atropine sulfate Drugs 0.000 claims 1
- 229960000686 benzalkonium chloride Drugs 0.000 claims 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 1
- 150000001642 boronic acid derivatives Chemical class 0.000 claims 1
- 229960003431 cetrimonium Drugs 0.000 claims 1
- RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 claims 1
- 229960004926 chlorobutanol Drugs 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 229940054534 ophthalmic solution Drugs 0.000 claims 1
- 239000002997 ophthalmic solution Substances 0.000 claims 1
- 125000005430 oxychloro group Chemical group 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229920005862 polyol Polymers 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 1
- 229960004919 procaine Drugs 0.000 claims 1
- 230000004515 progressive myopia Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 229960001922 sodium perborate Drugs 0.000 claims 1
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462016502P | 2014-06-24 | 2014-06-24 | |
| US201462096433P | 2014-12-23 | 2014-12-23 | |
| US201562151926P | 2015-04-23 | 2015-04-23 | |
| US14/726,139 US9421199B2 (en) | 2014-06-24 | 2015-05-29 | Ophthalmic composition |
| PCT/US2015/037249 WO2015200361A1 (en) | 2014-06-24 | 2015-06-23 | Ophthalmic composition |
| EP15811865.3A EP3160471B1 (en) | 2014-06-24 | 2015-06-23 | Ophthalmic compositions comprising a muscarinic antagonist and deuterated water |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220972T1 true HRP20220972T1 (hr) | 2022-11-25 |
Family
ID=54868660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220972TT HRP20220972T1 (hr) | 2014-06-24 | 2015-06-23 | Oftalmološki pripravci koji sadrže muskarinski antagonist i deuteriranu vodu |
Country Status (25)
| Country | Link |
|---|---|
| US (13) | US9421199B2 (enExample) |
| EP (3) | EP4115884A1 (enExample) |
| JP (6) | JP6678362B2 (enExample) |
| KR (4) | KR102710491B1 (enExample) |
| CN (3) | CN110638749A (enExample) |
| BR (1) | BR112016030368B1 (enExample) |
| CA (1) | CA2953363C (enExample) |
| CY (1) | CY1125505T1 (enExample) |
| DK (1) | DK3160471T3 (enExample) |
| ES (1) | ES2924243T3 (enExample) |
| FI (1) | FIC20250034I1 (enExample) |
| FR (1) | FR25C1045I1 (enExample) |
| HR (1) | HRP20220972T1 (enExample) |
| HU (2) | HUE059521T2 (enExample) |
| IL (1) | IL249643B (enExample) |
| LT (1) | LT3160471T (enExample) |
| NO (1) | NO2025049I1 (enExample) |
| PL (1) | PL3160471T3 (enExample) |
| PT (1) | PT3160471T (enExample) |
| RS (1) | RS63486B1 (enExample) |
| SG (3) | SG10201707617VA (enExample) |
| SI (1) | SI3160471T1 (enExample) |
| SM (1) | SMT202200447T1 (enExample) |
| TW (4) | TWI855319B (enExample) |
| WO (1) | WO2015200361A1 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2887923T3 (pl) | 2012-08-24 | 2023-08-14 | Sun Pharmaceutical Industries Limited | Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu |
| WO2016172712A2 (en) * | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| US10010502B2 (en) | 2015-05-19 | 2018-07-03 | Amorphex Therapeutics Llc | Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation |
| US11052094B2 (en) | 2015-05-29 | 2021-07-06 | Sydnexis, Inc. | D2O stabilized pharmaceutical formulations |
| DK3373976T3 (da) | 2015-11-10 | 2024-04-02 | Sun Pharmaceutical Ind Ltd | Topiske formuleringer og anvendelser deraf |
| NZ785158A (en) | 2016-02-29 | 2025-03-28 | Sun Pharmaceutical Ind Ltd | Topical cyclosporine-containing formulations and uses thereof |
| WO2017177262A1 (en) * | 2016-04-11 | 2017-10-19 | University Of Canberra | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |
| US20210267885A1 (en) * | 2016-05-25 | 2021-09-02 | Singapore Health Services Ptel Ltd | Atropine-containing aqueous composition |
| EP3585386A4 (en) * | 2017-02-21 | 2020-12-30 | Singapore Health Services PTE Ltd | COMPOSITION AND PROCESS FOR PREVENTING OR DELAYING THE ONCE OF MYOPIA INCLUDING ATROPINE |
| SG11201907315PA (en) * | 2017-03-23 | 2019-09-27 | Singapore Health Serv Pte Ltd | Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient |
| CN114617999B (zh) | 2017-03-27 | 2024-12-27 | 里珍纳龙药品有限公司 | 灭菌方法 |
| EP3970694A1 (en) * | 2017-05-11 | 2022-03-23 | Vyluma Inc. | Atropine pharmaceutical compositions |
| KR102643190B1 (ko) | 2017-06-10 | 2024-03-04 | 아이노비아 인코포레이티드 | 유체를 취급하기 위한, 그리고 눈에 유체를 전달하기 위한 디바이스들 |
| EP3654964B1 (en) * | 2017-07-20 | 2024-04-24 | Seinda Pharmaceutical Guangzhou Corporation | Composition comprising atropine and a miotic agent and its use in the treatment of myopia |
| EP3713530A4 (en) * | 2017-11-21 | 2021-08-18 | Sydnexis, Inc. | OPHTHALMIC COMPOSITION AND DELIVERY DEVICE FOR IT |
| US11524032B2 (en) | 2018-01-05 | 2022-12-13 | University Of Utah Research Foundation | Treatment of myopic progression |
| CN110934869B (zh) * | 2018-09-25 | 2023-07-04 | 沈阳兴齐眼药股份有限公司 | 一种阿托品药物组合物和药盒产品 |
| CN114533652B (zh) * | 2018-09-25 | 2024-12-13 | 沈阳兴齐眼药股份有限公司 | 药物组合物、其制备方法和用途 |
| CN115350148A (zh) * | 2019-02-06 | 2022-11-18 | 特清公司 | 用于从包含络合剂的眼用制剂中去除防腐剂的系统和方法 |
| MA52857A (fr) | 2019-03-01 | 2021-04-21 | Medivis S R L | Formulations ophtalmiques à base d'atropine |
| ES2988090T3 (es) * | 2019-03-26 | 2024-11-19 | Aura Biosciences Inc | Formulaciones de partículas similares a virus |
| WO2020219707A1 (en) * | 2019-04-24 | 2020-10-29 | Allergan, Inc. | Compositions and methods for treatment of ocular conditions |
| KR102308566B1 (ko) * | 2019-05-28 | 2021-10-05 | 서울대학교병원 | 녹내장 안약의 약물이상반응 진단 키트 |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| EP3996644A4 (en) * | 2019-07-11 | 2023-07-26 | University of Utah Research Foundation | MULTI-AGENT OCULAR FORMULATIONS AND METHODS OF TREATMENT |
| US20220411482A1 (en) * | 2019-11-15 | 2022-12-29 | Silk Technologies, Ltd. | Stable formulations of silk-derived protein |
| WO2021119513A1 (en) | 2019-12-11 | 2021-06-17 | Eyenovia, Inc. | Systems and devices for delivering fluids to the eye and methods of use |
| JP2023505841A (ja) * | 2019-12-16 | 2023-02-13 | シドネキシス，インク． | Ｄ２ｏを含む眼科用組成物 |
| CN111821259A (zh) * | 2020-07-14 | 2020-10-27 | 艾尔健康眼药(辽宁)有限公司 | 一种眼用药物组合物 |
| WO2022026796A1 (en) * | 2020-07-31 | 2022-02-03 | Altaire Pharmaceuticals, Inc. | Ophthalmic compositions for delivering meibum-like materials |
| US11850249B2 (en) | 2020-10-05 | 2023-12-26 | Somerset Therapeutics, Llc | Methods of efficiently reducing intraocular pressure |
| US11191751B1 (en) * | 2020-10-08 | 2021-12-07 | Ads Therapeutics Llc | Topical ophthalmological atropine free base compositions |
| CN114306331B (zh) * | 2020-10-10 | 2023-07-18 | 远大生命科学(武汉)有限公司 | 戊乙奎醚在治疗或预防视力损伤性眼部疾病中的用途 |
| KR102245533B1 (ko) * | 2020-11-02 | 2021-04-28 | 주식회사 지게차코리아 | 운송수단용 림 및 이의 제조방법 |
| US11872213B2 (en) | 2021-01-28 | 2024-01-16 | Glaukos Corporation | Formulations |
| EP4288151A4 (en) | 2021-02-03 | 2025-01-01 | ADS Therapeutics LLC | Topical ophthalmological compositions |
| US20240139166A1 (en) * | 2021-02-04 | 2024-05-02 | Sydnexis, Inc. | Ophthalmic compositions for presbyopia |
| WO2022172089A1 (en) * | 2021-02-12 | 2022-08-18 | I Optima Ltd. | Compound, method and system for ophthalmic surgery |
| US20240156724A1 (en) * | 2021-03-16 | 2024-05-16 | Vyluma Inc. | Multi-Dose Container for Ophthalmic Compositions |
| EP4088714A1 (en) | 2021-05-10 | 2022-11-16 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Ophthalmic pharmaceutical composition comprising atropine |
| EP4088713A1 (en) | 2021-05-10 | 2022-11-16 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Ophthalmic pharmaceutical composition comprising atropine |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| CN117295491A (zh) * | 2021-09-13 | 2023-12-26 | 安徽欧普视方医药科技有限公司 | 阿托品滴眼液及其制备方法 |
| US12396534B2 (en) | 2021-10-08 | 2025-08-26 | Johnson & Johnson Vision Care, Inc. | Multi-material lens package |
| WO2023081891A2 (en) * | 2021-11-05 | 2023-05-11 | Calm Water Therapeutics Llc | Methods for using bioadhesive and steric interactions of copolymers with at least two moieties to minimize adverse effects mediated by external influences on cell, tissue, organ system, and organism biology |
| US20230277521A1 (en) * | 2022-03-07 | 2023-09-07 | Harrow Ip, Llc | Extended-release pharmaceutical compositions for treating eye conditions |
| WO2023172240A1 (en) * | 2022-03-07 | 2023-09-14 | Harrow Ip, Llc | Extended-release pharmaceutical compositions for treating eye conditions |
| WO2023171989A1 (ko) * | 2022-03-11 | 2023-09-14 | 주식회사 메디치바이오 | 안질환 예방 또는 치료용 약학 조성물 |
| EP4698187A2 (en) * | 2022-05-03 | 2026-02-25 | IVIEW Therapeutics, Inc. | Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of eye diseases |
| WO2024015959A1 (en) | 2022-07-15 | 2024-01-18 | Praful Doshi | Methods of making and using contact lenses including medicaments and stabilizers of labile components such as drugs |
| US20240033260A1 (en) * | 2022-07-26 | 2024-02-01 | The Chinese University Of Hong Kong | Low-concentration atropine for myopia prevention (lamp-2) study |
| US20260083720A1 (en) * | 2022-10-26 | 2026-03-26 | Vyluma Inc. | Childhood Atropine For Myopia Progression |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| US20240316028A1 (en) * | 2023-03-16 | 2024-09-26 | Glaukos Corporation | Ophthalmic cream formulations and their uses |
| TW202525288A (zh) * | 2023-10-26 | 2025-07-01 | 英商庫博光學國際有限公司 | 液體組合物 |
| WO2025212792A1 (en) * | 2024-04-03 | 2025-10-09 | Sydnexis, Inc. | Methods and compositions for increasing pupil dilation |
| TW202610651A (zh) * | 2024-08-13 | 2026-03-16 | 英商庫博光學國際有限公司 | 液體組合物 |
Family Cites Families (141)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4382124B1 (en) | 1958-07-18 | 1994-10-04 | Rohm & Haas | Process for preparing macroreticular resins, copolymers and products of said process |
| NL284933A (enExample) | 1961-10-31 | |||
| DE1518819B1 (de) | 1965-04-03 | 1969-12-04 | Basf Ag | Loesungsvermittler fuer pharmazeutische Zwecke |
| SE352811B (enExample) | 1971-06-04 | 1973-01-15 | Pharmacia Ab | |
| US4014335A (en) | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
| US4255415A (en) * | 1978-11-22 | 1981-03-10 | Schering Corporation | Polyvinyl alcohol ophthalmic gel |
| US4952586A (en) | 1982-08-27 | 1990-08-28 | The Regents Of The University Of California | Edrophonium-atropine composition and therapeutic uses thereof |
| US4474751A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
| DE3644984A1 (de) | 1986-07-01 | 1988-07-07 | Eberhardt Schlueter | Patrone oder ampulle fuer eine injektionsvorrichtung sowie selbsttaetige injektionsvorrichtung |
| US5147647A (en) | 1986-10-02 | 1992-09-15 | Sohrab Darougar | Ocular insert for the fornix |
| US4852582A (en) | 1987-09-11 | 1989-08-01 | Pell Donald M | Method and kit for measuring the effectiveness of bronchodilators |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| IL85312A (en) | 1988-02-03 | 1991-08-16 | Israel State | Injectable pharmaceutical compositions having improved stability |
| JP2617508B2 (ja) * | 1988-02-05 | 1997-06-04 | エーザイ株式会社 | 安定なジフェンヒドラミン含有水溶液 |
| US5702716A (en) | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| FR2638428B1 (fr) | 1988-10-28 | 1990-12-28 | Transphyto Sa | Conditionnement pour liquides a epurer |
| US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US5496471A (en) | 1990-01-08 | 1996-03-05 | Ciba-Geigy Corporation | Apparatus for removing components from solutions |
| JP3256997B2 (ja) | 1990-08-30 | 2002-02-18 | 千寿製薬株式会社 | 安定な水性製剤 |
| US5259998A (en) | 1991-10-04 | 1993-11-09 | Chiron Ophthalmics, Inc. | Method for casting dissolvable ophthalmic shields in a mold |
| US5492689A (en) | 1991-11-19 | 1996-02-20 | The Center For Innovative Technology | Combined virustatic antimediator (COVAM) treatment of common colds |
| US5716952A (en) | 1992-03-18 | 1998-02-10 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists |
| SK143893A3 (en) | 1992-03-18 | 1994-05-11 | Cooper Vision Pharmaceuticals | Verapamil hci formulation and other opthalmic solutions with buffer system for ocular administration |
| US5505953A (en) | 1992-05-06 | 1996-04-09 | Alcon Laboratories, Inc. | Use of borate-polyol complexes in ophthalmic compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US5260000A (en) | 1992-08-03 | 1993-11-09 | Bausch & Lomb Incorporated | Process for making silicone containing hydrogel lenses |
| FR2702660B1 (fr) | 1993-03-17 | 1995-05-24 | Karl Simpson | Compositions thérapeutiques stabilisées et leur procédé de préparation. |
| US5840770A (en) | 1993-08-24 | 1998-11-24 | Hill Medical Corporation | Method of killing tumor cells |
| US5490938A (en) | 1993-12-20 | 1996-02-13 | Biopolymerix, Inc. | Liquid dispenser for sterile solutions |
| SE9401108D0 (sv) | 1994-03-31 | 1994-03-31 | Leiras Oy | Ophthalmic composition I |
| EP1125577B1 (en) | 1994-04-08 | 2006-02-15 | QLT USA, Inc. | Liquid drug delivery compositions |
| GB2293100A (en) | 1994-09-15 | 1996-03-20 | Medeva Europ Ltd | Pharmaceutical compositions with deuterium oxide |
| CZ285636B6 (cs) | 1995-02-07 | 1999-10-13 | Ústav Makromolekulární Chemie Av Čr | Nové lékové formy pro farmaka aplikovaná v očním lékařství s prolongovanou účinností a způsob jejich výroby |
| WO1997016192A1 (en) | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Muscarine antagonists |
| FR2742357B1 (fr) | 1995-12-19 | 1998-01-09 | Rhone Poulenc Rorer Sa | Nanoparticules stabilisees et filtrables dans des conditions steriles |
| CA2250780A1 (en) | 1996-04-10 | 1997-10-16 | The Regents Of The University Of California | Correction of genetic defects using chemical chaperones |
| US6270954B1 (en) | 1996-04-10 | 2001-08-07 | The Regents Of The University Of California | Correction of genetic defects using chemical chaperones |
| US20030157187A1 (en) | 1996-12-02 | 2003-08-21 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing inflammatory diseases |
| US20040136915A1 (en) | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing atropine |
| FR2770843B1 (fr) | 1997-11-13 | 2000-01-14 | Lavipharm Lab | Association prolamines-lipides polaires vegetaux, son procede de preparation et ses applications |
| US6149670A (en) | 1999-03-11 | 2000-11-21 | Alsius Corporation | Method and system for treating cardiac arrest using hypothermia |
| US5976499A (en) | 1998-09-04 | 1999-11-02 | Johns Hopkins University | Macroscopic sweat test for cystic fibrosis |
| IN185228B (enExample) | 1999-02-03 | 2000-12-09 | Bakulesh Mafatlal Dr Khamar | |
| CA2374003C (en) | 1999-05-17 | 2008-02-12 | Aesgen, Inc. | Improved cellular uptake of bioactive agents |
| JP4757970B2 (ja) * | 1999-10-14 | 2011-08-24 | 久光製薬株式会社 | 点眼剤組成物 |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| US6218428B1 (en) | 2000-04-28 | 2001-04-17 | Emil Chynn | Ophthalmic composition |
| CN1323595A (zh) | 2000-05-11 | 2001-11-28 | 朱卫国 | 用于青光眼的药物组合物 |
| US20050251254A1 (en) | 2000-06-02 | 2005-11-10 | Brady Daniel G | Method of implanting accommodating intraocular lenses |
| JP5000835B2 (ja) | 2000-08-25 | 2012-08-15 | 千寿製薬株式会社 | 水性懸濁液剤 |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| CN1509172A (zh) | 2001-05-25 | 2004-06-30 | ά����ҩ��˾ | 哌仑西平眼用凝胶剂 |
| JP2003063576A (ja) | 2001-06-15 | 2003-03-05 | Taisei Kako Co Ltd | 分与容器 |
| CN1206988C (zh) | 2002-05-10 | 2005-06-22 | 刘继东 | 硫酸阿托品眼用凝胶 |
| MXPA06001776A (es) | 2003-08-15 | 2007-09-07 | Qlt Usa Inc | Sistema de suministro de farmaco transmucosal biocorrosivo, adhesivo. |
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| WO2005072656A1 (en) | 2004-01-27 | 2005-08-11 | Osteotech, Inc. | Stabilized bone graft |
| US20050232972A1 (en) | 2004-04-15 | 2005-10-20 | Steven Odrich | Drug delivery via punctal plug |
| US8313763B2 (en) | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
| US7659260B2 (en) | 2005-01-14 | 2010-02-09 | Eddie Francis Kadrmas | Tamponade compositions and methods for retinal repair |
| MX2007009417A (es) | 2005-02-04 | 2007-08-17 | Univ Auburn | Sistema de suministro de farmaco de contacto. |
| US9238003B2 (en) | 2005-02-04 | 2016-01-19 | Auburn University | Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules |
| CN1939534B (zh) | 2005-09-27 | 2010-12-01 | 长春金赛药业股份有限公司 | 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂 |
| GB2423711B (en) * | 2005-10-24 | 2007-02-14 | Fortune Apex Dev Ltd | Method for preparing a pharmaceutical composition with enhanced mucoadhesion |
| WO2007053747A2 (en) | 2005-11-01 | 2007-05-10 | President And Fellows Of Harvard College | Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosis |
| US7767217B2 (en) | 2006-03-14 | 2010-08-03 | Foresight Biotherapeutics | Ophthalmic compositions comprising povidone-iodine |
| CN101049287A (zh) * | 2006-04-07 | 2007-10-10 | 财团法人长庚纪念医院 | 抑制近视度数增加的低浓度阿托平眼药剂及其制造方法 |
| US20070254914A1 (en) * | 2006-05-01 | 2007-11-01 | Non-Profit Organization Chang Gung Memorial Hospital | Low-concentration atropine solution for preventing myopia progression and preparing method thereof |
| JP2007308398A (ja) * | 2006-05-17 | 2007-11-29 | Chang Gung Memorial Hospital | 目薬、及びその製造方法 |
| US7691099B2 (en) * | 2006-07-12 | 2010-04-06 | Ntk Enterprises, Inc. | Deuterated ocular solutions for LTK and other surgical eye procedures |
| EP2123278B1 (en) | 2007-02-07 | 2013-01-09 | Teika Pharmaceutical Co., Ltd. | Eye drop preparation comprising latanoprost |
| WO2008151179A2 (en) | 2007-06-04 | 2008-12-11 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamines |
| CN101327216A (zh) | 2007-06-22 | 2008-12-24 | 肖正连 | 一种硫酸阿托品眼用即型凝胶 |
| CA2702082A1 (en) * | 2007-10-08 | 2009-04-16 | Fovea Pharmaceuticals Sa | Aqueous ophthalmic formulations |
| US7815605B2 (en) | 2007-11-28 | 2010-10-19 | Souter Steve R | Emergency medication pump injection system |
| CN101468214A (zh) * | 2007-12-27 | 2009-07-01 | 上海华捷视医疗设备有限公司 | 一种眼科手术用重水及其制备方法 |
| ITRM20080182A1 (it) | 2008-04-07 | 2009-10-08 | Medivis S R L | Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma. |
| ES2459198T3 (es) | 2008-04-20 | 2014-05-08 | D2 Bioscience Group Ltd | Utilización de óxido de deuterio como inhibidor de elastasa |
| EP2962682B1 (en) | 2008-12-11 | 2018-03-28 | Massachusetts Institute Of Technology | Method of making a contact lens drug delivery device |
| DE102009003942A1 (de) | 2009-01-07 | 2010-07-08 | D2O Biosience Group Ltd., Hamilton | Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges |
| US8883214B2 (en) | 2009-01-13 | 2014-11-11 | The Regents Of The University Of California | Implantable delivery vehicle for ocular delivery of muscarinic antagonists |
| TW201043211A (en) | 2009-03-31 | 2010-12-16 | Johnson & Johnson Vision Care Inc | Punctal plugs |
| US20120203161A1 (en) * | 2009-08-12 | 2012-08-09 | Seros Medical, Llc | Deuterated water and riboflavin solution for extending singlet oxygen lifetimes in treatment of ocular tissue and method of use |
| FR2950036B1 (fr) | 2009-09-11 | 2011-12-16 | Rexam Pharma La Verpilliere | Dispositif de distribution de liquide |
| FR2952040B1 (fr) | 2009-10-29 | 2011-12-30 | Rexam Pharma La Verpilliere | Dispositif de distribution de liquide sous forme de gouttes |
| WO2011098578A2 (en) | 2010-02-12 | 2011-08-18 | Bioneer A/S | Liposome system for ocular administration |
| US8945101B2 (en) * | 2010-04-30 | 2015-02-03 | Seros Medical, Llc | Method and apparatus for treatment of ocular tissue using combine modalities |
| TWI424663B (zh) | 2010-07-01 | 2014-01-21 | Joy Ride Tech Co Ltd | A motor with heat pipe |
| AU2011278934B2 (en) | 2010-07-15 | 2015-02-26 | Eyenovia, Inc. | Drop generating device |
| MX2013000604A (es) | 2010-07-15 | 2013-07-05 | Corinthian Ophthalmic Inc | Suministro oftálmico de fármaco. |
| JP5823766B2 (ja) | 2010-07-30 | 2015-11-25 | 大塚製薬株式会社 | 医薬組成物 |
| TW201217533A (en) | 2010-08-04 | 2012-05-01 | Bayer Pharma AG | Genomics of actinoplanes utahensis |
| US8530449B2 (en) | 2010-09-09 | 2013-09-10 | Assad S. Sawaya | Composition for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye |
| EP2675455A4 (en) * | 2011-02-18 | 2014-07-16 | M S Appasamy Associates | OPHTHALMIC COMPOSITION FOR DILATING PUPILS |
| JP2014506936A (ja) | 2011-03-03 | 2014-03-20 | アラーガン インコーポレイテッド | シリコーンベースの眼科製剤 |
| EP2694048B1 (en) | 2011-04-05 | 2020-10-07 | Optosolve Research & Development Ltd | Ophthalmic treatments |
| MX360666B (es) | 2011-05-12 | 2018-11-13 | Foresight Biotherapeutics Inc | Composiciones de yodopovidona estables con antiinflamatorios esteroides y no esteroides. |
| WO2012161655A1 (en) | 2011-05-23 | 2012-11-29 | Singapore Health Services Pte Ltd | Composition and/or method for reducing and/or preventing myopia progression comprising atropine |
| TW201302244A (zh) | 2011-07-08 | 2013-01-16 | Univ Nat Chiao Tung | 載藥型隱形眼鏡及其製備方法 |
| US20140350049A1 (en) | 2011-11-29 | 2014-11-27 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of darier disease |
| US20170304152A1 (en) | 2012-02-01 | 2017-10-26 | Certa Dose, Inc. | Apparatuses, methods, and systems for delivering medication using medication kits |
| US20130303627A1 (en) | 2012-02-27 | 2013-11-14 | Rohto Pharmaceutical Co., Ltd. | Ophthalmic composition |
| US9814729B2 (en) | 2012-03-14 | 2017-11-14 | The Regents Of The University Of California | Nerve agent antidotes |
| AU2013245946A1 (en) | 2012-04-10 | 2014-11-27 | Eyenovia, Inc. | Spray ejector mechanisms and devices providing charge isolation and controllable droplet charge, and low dosage volume opthalmic administration |
| US9056057B2 (en) | 2012-05-03 | 2015-06-16 | Kala Pharmaceuticals, Inc. | Nanocrystals, compositions, and methods that aid particle transport in mucus |
| US8765725B2 (en) | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| BR112014028069A2 (pt) | 2012-05-11 | 2017-08-08 | Cipla Ltd | composição farmacêutica oftálmica, processo para a preparação de uma composição farmacêutica oftálmica, uso de uma composição farmacêutica oftálmica, e, método para a prevenção ou tratamento de uma infecção fúngica |
| IN2014DN10521A (enExample) | 2012-05-14 | 2015-08-21 | Corinthian Ophthalmic Inc | |
| SG11201407431RA (en) | 2012-05-15 | 2014-12-30 | Eyenovia Inc | Ejector devices, methods, drivers, and circuits therefor |
| US20150297800A1 (en) | 2012-07-03 | 2015-10-22 | Sio2 Medical Products, Inc. | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS |
| US9827250B2 (en) * | 2012-07-31 | 2017-11-28 | Johnson & Johnson Vision Care, Inc. | Lens incorporating myopia control optics and muscarinic agents |
| PL2887923T3 (pl) | 2012-08-24 | 2023-08-14 | Sun Pharmaceutical Industries Limited | Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu |
| US9498035B2 (en) | 2012-12-21 | 2016-11-22 | Coopervision International Holding Company, Lp | Silicone hydrogel contact lenses for sustained release of beneficial polymers |
| WO2014140105A1 (en) | 2013-03-13 | 2014-09-18 | D2 Bioscience Group Ltd. | Materials and compositions for dental cements and filler materials |
| WO2014161002A2 (en) | 2013-03-29 | 2014-10-02 | Onefocus Technology, Llc | Drug delivery from contact lenses with a fluidic module |
| WO2014182620A1 (en) | 2013-05-06 | 2014-11-13 | Kaohsiung Chang Gung Memorial Hospital | Pharmaceutical composition and uses thereof |
| CR20190156A (es) | 2013-05-17 | 2019-05-16 | Incyte Corp | Derivados de bipirazol como inhibidores jak |
| US9089562B2 (en) | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US9320709B2 (en) | 2013-08-28 | 2016-04-26 | Presbyopia Therapies Llc | Storage stable compositions and methods for the treatment of refractive errors of the eye |
| DE102013218802B4 (de) | 2013-09-19 | 2018-06-28 | Aero Pump Gmbh | Abgabevorrichtung für Fluide aus einem Fluidbehälter |
| WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| US20160009705A1 (en) | 2014-06-24 | 2016-01-14 | Sydnexis, Inc. | Ophthalmic composition |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| WO2016025560A1 (en) | 2014-08-13 | 2016-02-18 | University Of Florida Research Foundation, Inc. | Preservative removal from eye drops |
| DE102015104646B3 (de) | 2015-03-26 | 2016-06-30 | Aero Pump Gmbh | Abgabevorrichtung für ein Fluid |
| US11052094B2 (en) | 2015-05-29 | 2021-07-06 | Sydnexis, Inc. | D2O stabilized pharmaceutical formulations |
| WO2016205071A1 (en) | 2015-06-18 | 2016-12-22 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| US20210267885A1 (en) | 2016-05-25 | 2021-09-02 | Singapore Health Services Ptel Ltd | Atropine-containing aqueous composition |
| EP3478269A4 (en) | 2016-06-29 | 2020-04-08 | Otonomy, Inc. | OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES |
| KR102472774B1 (ko) | 2016-08-19 | 2022-11-30 | 오라시스 파마슈티칼스 엘티디. | 안과용 약학 조성물 및 이와 관련된 용도 |
| JP6781829B2 (ja) | 2016-09-19 | 2020-11-04 | メキシケム フロー エセ・ア・デ・セ・ヴェ | 医薬組成物 |
| EP3585386A4 (en) | 2017-02-21 | 2020-12-30 | Singapore Health Services PTE Ltd | COMPOSITION AND PROCESS FOR PREVENTING OR DELAYING THE ONCE OF MYOPIA INCLUDING ATROPINE |
| EP3970694A1 (en) | 2017-05-11 | 2022-03-23 | Vyluma Inc. | Atropine pharmaceutical compositions |
| EP3654964B1 (en) | 2017-07-20 | 2024-04-24 | Seinda Pharmaceutical Guangzhou Corporation | Composition comprising atropine and a miotic agent and its use in the treatment of myopia |
| EP3713530A4 (en) | 2017-11-21 | 2021-08-18 | Sydnexis, Inc. | OPHTHALMIC COMPOSITION AND DELIVERY DEVICE FOR IT |
| DK3870170T3 (da) | 2018-10-26 | 2026-05-26 | Opus Genetics Inc | Behandling af presbyopi og mydriasis med fentolamin |
| JP2023505841A (ja) | 2019-12-16 | 2023-02-13 | シドネキシス，インク． | Ｄ２ｏを含む眼科用組成物 |
| US20240139166A1 (en) | 2021-02-04 | 2024-05-02 | Sydnexis, Inc. | Ophthalmic compositions for presbyopia |
| WO2025212792A1 (en) | 2024-04-03 | 2025-10-09 | Sydnexis, Inc. | Methods and compositions for increasing pupil dilation |
-
2015
- 2015-05-29 US US14/726,139 patent/US9421199B2/en active Active
- 2015-06-23 PT PT158118653T patent/PT3160471T/pt unknown
- 2015-06-23 JP JP2016574898A patent/JP6678362B2/ja active Active
- 2015-06-23 WO PCT/US2015/037249 patent/WO2015200361A1/en not_active Ceased
- 2015-06-23 SG SG10201707617VA patent/SG10201707617VA/en unknown
- 2015-06-23 SG SG10201913976SA patent/SG10201913976SA/en unknown
- 2015-06-23 KR KR1020217029081A patent/KR102710491B1/ko active Active
- 2015-06-23 DK DK15811865.3T patent/DK3160471T3/da active
- 2015-06-23 HR HRP20220972TT patent/HRP20220972T1/hr unknown
- 2015-06-23 PL PL15811865.3T patent/PL3160471T3/pl unknown
- 2015-06-23 SG SG11201610682UA patent/SG11201610682UA/en unknown
- 2015-06-23 KR KR1020177002056A patent/KR102506109B1/ko active Active
- 2015-06-23 EP EP22175801.4A patent/EP4115884A1/en active Pending
- 2015-06-23 EP EP20159621.0A patent/EP3689350A1/en active Pending
- 2015-06-23 HU HUE15811865A patent/HUE059521T2/hu unknown
- 2015-06-23 CN CN201910968378.3A patent/CN110638749A/zh active Pending
- 2015-06-23 SI SI201531871T patent/SI3160471T1/sl unknown
- 2015-06-23 CA CA2953363A patent/CA2953363C/en active Active
- 2015-06-23 KR KR1020197038476A patent/KR20200001612A/ko not_active Ceased
- 2015-06-23 BR BR112016030368-7A patent/BR112016030368B1/pt active IP Right Grant
- 2015-06-23 KR KR1020247031630A patent/KR20240144477A/ko active Pending
- 2015-06-23 CN CN202210803133.7A patent/CN115192520A/zh active Pending
- 2015-06-23 LT LTEPPCT/US2015/037249T patent/LT3160471T/lt unknown
- 2015-06-23 ES ES15811865T patent/ES2924243T3/es active Active
- 2015-06-23 SM SM20220447T patent/SMT202200447T1/it unknown
- 2015-06-23 EP EP15811865.3A patent/EP3160471B1/en active Active
- 2015-06-23 CN CN201580045735.9A patent/CN106572998B/zh active Active
- 2015-06-23 RS RS20220765A patent/RS63486B1/sr unknown
- 2015-06-24 TW TW111113844A patent/TWI855319B/zh active
- 2015-06-24 TW TW113145339A patent/TW202510877A/zh unknown
- 2015-06-24 TW TW104120379A patent/TWI763620B/zh active
- 2015-06-24 TW TW112131152A patent/TWI867694B/zh active
-
2016
- 2016-04-25 US US15/568,381 patent/US10842787B2/en active Active
- 2016-07-12 US US15/208,537 patent/US9770447B2/en active Active
- 2016-12-19 IL IL249643A patent/IL249643B/en unknown
-
2017
- 2017-07-27 US US15/661,816 patent/US10076515B2/en active Active
-
2018
- 2018-02-13 US US15/895,933 patent/US10201534B2/en active Active
- 2018-12-18 US US16/224,286 patent/US10864208B2/en active Active
-
2019
- 2019-11-07 US US16/677,538 patent/US11382909B2/en active Active
-
2020
- 2020-01-30 JP JP2020014108A patent/JP7505888B2/ja active Active
- 2020-11-13 US US17/097,930 patent/US11596625B2/en active Active
-
2022
- 2022-01-12 JP JP2022003408A patent/JP7863278B2/ja active Active
- 2022-08-23 CY CY20221100568T patent/CY1125505T1/el unknown
- 2022-11-16 US US18/055,949 patent/US11883390B2/en active Active
- 2022-11-16 US US18/055,945 patent/US11896588B2/en active Active
- 2022-11-16 US US18/055,940 patent/US11890277B2/en active Active
-
2023
- 2023-10-19 JP JP2023180519A patent/JP7863279B2/ja active Active
- 2023-12-14 US US18/539,823 patent/US12629360B2/en active Active
-
2025
- 2025-05-12 JP JP2025080139A patent/JP2025131595A/ja active Pending
- 2025-11-25 HU HUS2500044C patent/HUS2500044I1/hu unknown
- 2025-11-26 FR FR25C1045C patent/FR25C1045I1/fr active Active
- 2025-11-26 NO NO2025049C patent/NO2025049I1/no unknown
- 2025-11-28 FI FIC20250034C patent/FIC20250034I1/fi unknown
- 2025-12-16 JP JP2025256875A patent/JP2026064997A/ja active Pending
-
2026
- 2026-03-19 US US19/572,547 patent/US20260216167A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220762T1 (hr) | Upotreba pilokarpin-hidroklorida u liječenju prezbiopije | |
| JP2022062045A5 (enExample) | ||
| JP2018521000A5 (enExample) | ||
| HRP20191667T1 (hr) | Vodenasta oftalmološka otopina i postupak tretmana sindroma suhog oka | |
| JP2017522292A5 (enExample) | ||
| MX385798B (es) | Composiciones orales que contienen un ester de 17-hidroxiprogesterona y metodos relacionados. | |
| MX2017016823A (es) | Composiciones orales que contienen éster de 17- hydroxiprogesterona y métodos relacionados. | |
| HRP20200889T1 (hr) | Upotreba dugodjelujućih peptida glp-1 | |
| MX2022014313A (es) | Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada. | |
| RU2012101782A (ru) | Водные фармацевтические композиции, содержащие комплексы боратполиол | |
| WO2016172712A3 (en) | Ophthalmic composition | |
| HRP20170419T1 (hr) | Sastavi za liječenje središnje posredovane mučnine i povraćanja | |
| RU2013129222A (ru) | Глазные композиции, содержащие мукоадгезивные полисахариды, способные стимулировать восстановление эпителия роговицы | |
| AR082150A1 (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio | |
| WO2007108541A1 (ja) | キサンタンガムおよびブドウ糖を含有する眼科用組成物 | |
| HRP20211515T1 (hr) | Stabilni farmaceutski pripravak u fiksnoj dozi koji sadrži mometazon i olopatadin, namijenjen nazalnoj primjeni | |
| HRP20241345T1 (hr) | Liječenje poremećaja gubitka kose deuteriranim inhibitorima jak | |
| RU2013142602A (ru) | Композиции и способы для нехирургического лечения птоза | |
| JP2016503058A5 (enExample) | ||
| HRP20130946T1 (hr) | Olopatadin nazalni sprej, namijenjen upotrebi kod djece | |
| TW202031263A (zh) | 抑制軟性隱形眼鏡變質之眼科用組成物 | |
| JP2023505841A5 (enExample) | ||
| FI4025188T3 (fi) | Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia | |
| KR20200088824A (ko) | 근시의 진행을 제어 및/또는 감소시키기 위한 약학 조성물 | |
| ES2899759T3 (es) | Composición hiperosmolar de ácido hialurónico |